--Advertisement--
Advertisement

Bauchi worst hit as NCDC reports 1,182 suspected cholera cases in one week

map of Bauchi state map of Bauchi state

The Nigeria Centre for Disease Control (NCDC), in its latest report, says 1,182 suspected cases were recorded in 13 states within one week.

The agency, in its epidemiological report for week 36 — September 6 to 12 — released on Monday, said 23 deaths were recorded within the one-week period in nine states.

According to the NCDC, there was a 58 percent decrease in the number of suspected cases in week 36, compared to week 35.

In the latest report, Bauchi recorded the highest figure of suspected cases with 472 infections, followed by Katsina with 194, while Borno recorded 106.

Advertisement

Other states with new cases are “Jigawa (95), Yobe (80), Kaduna (68), Adamawa (63), Sokoto (38), Gombe (34), Abia (13), Taraba (10), Ogun (8) and Niger (1)”.

Kaduna recorded the highest number of deaths in the reporting week with six fatalities, followed by Adamawa with five, while Katsina recorded four.

Other states that recorded deaths within the one-week period are “Gombe (2), Jigawa (2), Bauchi (1), Borno (1), Ogun (1) and Taraba (1)”.

Advertisement

As of September 12, 2021, a total of 72,910 suspected cholera cases, including 2,404 deaths, have been recorded in 27 states and the federal capital territory (FCT) since January 2021.

According to the NCDC, two new states — Abia and Ogun — reported cases in week 36.

“Twenty-seven states and FCT have reported suspected cholera cases in 2021. These are Abia, Adamawa, Bauchi, Bayelsa, Benue, Borno, Cross River, Delta, Ekiti, Enugu, FCT, Gombe, Jigawa, Kaduna, Kano, Katsina, Kebbi, Kogi, Kwara, Nasarawa, Niger, Ogun, Osun, Plateau, Sokoto, Taraba, Yobe, and Zamfara,” the report reads.

“There was a 58% decrease in the number of new suspected cases in week 36 (1,182) compared with week 35 (1,677).

Advertisement

“Bauchi (472), Katsina (194) and Borno (106) account for 65.3% of 1,182 suspected cases reported in week 36.”

Add a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

error: Content is protected from copying.